About
The Noah Medical Galaxy System is a next-generation robotic bronchoscopy platform designed to transform pulmonary diagnostics through AI-driven imaging and intelligent workflow automation. At its core is the proprietary TiLT+ Technology™ (Tool-in-Lesion Tomography), which integrates available C-arm fluoroscopy to overcome the common challenge of CT-to-body divergence — ensuring the bronchoscope tool is accurately positioned within the target lesion in real time. The platform consolidates advanced imaging, precision targeting, and adaptive workflow features into a single intelligent system. Clinical evidence supports its performance: a multi-center MATCH II Study of 31 patients demonstrated a 96.7% strict diagnostic yield, while a 100-patient cohort study at the Cleveland Clinic showed 95% diagnostic accuracy. Additionally, a 70-case community hospital study reported a 1.1 OR and 1.4 EndoSuite cost-benefit ratio, demonstrating economic efficiency alongside clinical effectiveness. The Galaxy System uses a single-use scope to maintain sterility and reduce cross-contamination risk. It is designed for interventional pulmonologists at academic medical centers, community hospitals, and specialized pulmonology practices seeking to improve diagnostic outcomes for peripheral lung lesions. By combining AI-enhanced imaging guidance with a streamlined procedural workflow, the Galaxy System reduces procedural complexity while maximizing lesion localization confidence — making it a compelling choice for institutions aiming to elevate their bronchoscopy programs.
Key Features
- TiLT+ Technology™ (Tool-in-Lesion Tomography): Proprietary real-time imaging technology that integrates C-arm fluoroscopy to confirm tool placement within the target lesion, overcoming CT-to-body divergence.
- High Diagnostic Yield: Clinically validated 96.7% strict diagnostic yield in the MATCH II multi-center study and 95% diagnostic accuracy in a 100-patient cohort at the Cleveland Clinic.
- Streamlined Procedural Workflow: Adaptive workflow features reduce procedural complexity, enabling faster and more efficient bronchoscopy sessions in both OR and EndoSuite environments.
- Single-Use Scope: A fully disposable bronchoscope scope eliminates reprocessing steps, reduces cross-contamination risk, and maintains sterility across procedures.
- Favorable Cost-Benefit Profile: Demonstrated 1.1 OR and 1.4 EndoSuite cost-benefit ratios in a community hospital study of 70 consecutive cases, supporting economic viability.
Use Cases
- Diagnosing peripheral pulmonary lesions with high accuracy using real-time robotic bronchoscopy guidance
- Reducing the need for surgical biopsy or repeat procedures through first-pass diagnostic confidence
- Streamlining bronchoscopy workflows in both OR and EndoSuite settings at community and academic hospitals
- Supporting clinical research on robotic bronchoscopy efficacy through integrated imaging data capture
- Improving cost-efficiency of pulmonary diagnostic programs by reducing procedure time and repeat interventions
Pros
- Industry-Leading Diagnostic Accuracy: Multi-center clinical data shows 95–96.7% diagnostic yield, significantly reducing the need for repeat procedures or surgical biopsy.
- Real-Time Lesion Confirmation: TiLT+ Technology™ provides live imaging confirmation that the tool is within the lesion, giving physicians greater procedural confidence.
- Economically Viable for Community Hospitals: Demonstrated cost-benefit ratios make the system accessible not just to large academic centers but also to community-based practices.
Cons
- Requires Compatible C-Arm Hardware: The imaging system depends on the availability of a compatible C-arm fluoroscopy unit, which may not be present in all facilities.
- Enterprise-Level Investment: As a capital medical device, upfront acquisition and integration costs may be prohibitive for smaller or resource-limited institutions.
Frequently Asked Questions
What is TiLT+ Technology™?
TiLT+ Technology™ stands for Tool-in-Lesion Tomography Plus. It is Noah Medical's proprietary imaging system that integrates C-arm fluoroscopy with robotic bronchoscopy to confirm in real time that the diagnostic tool is accurately positioned within the target lung lesion, compensating for CT-to-body divergence.
What diagnostic yield does the Galaxy System achieve?
Clinical studies show a 96.7% strict diagnostic yield in the MATCH II multi-center study and 95% diagnostic accuracy in a 100-patient prospective cohort study conducted at the Cleveland Clinic.
Does the Galaxy System use a reusable or single-use bronchoscope?
The Galaxy System uses a single-use bronchoscope scope, eliminating the need for reprocessing between procedures and reducing infection risk.
Is the Galaxy System suitable for community hospitals?
Yes. A study of 70 consecutive cases at a community hospital demonstrated cost-benefit ratios of 1.1 (OR) and 1.4 (EndoSuite), indicating economic feasibility beyond academic medical centers.
What type of facility or physician would benefit most from the Galaxy System?
The Galaxy System is designed for interventional pulmonologists in hospitals and specialty clinics performing bronchoscopic evaluation of peripheral lung lesions, particularly those seeking to improve diagnostic accuracy and procedural efficiency.
